Abstract 195P
Background
The systemic immunological effects of combining anti-CTLA4 therapy with PD-(L)1 blockade remain incompletely characterized, despite the widespread use of this combination in treating various solid tumors. We investigated the additive impact of anti-CTLA4 on peripheral immune signatures in patients undergoing PD-(L)1 blockade, using serial blood samples from a cohort of patients receiving checkpoint inhibitor therapy for advanced solid tumors.
Methods
We prospectively collected serial blood specimens from adult patients receiving treatment with anti-PD(L)1 alone or in combination with anti-CTLA4 therapy for advanced, unresectable solid tumors at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. We performed in-parallel analysis of peripheral blood mononuclear cells (PBMC) using Cytometry by Time-of-Flight (CyTOF), and plasma cytokines using Luminex immunoassay on specimens collected at baseline and early on treatment (month 1 or 2).
Results
Our study cohort included 109 patients [anti-PD(L)1 alone, n=58, in combination with anti-CTLA4, n=51]. As compared to single-agent anti-PD(L)1, combination therapy was associated with a greater expansion of CD4+ helper subsets, including Th17 (adjusted p=0.039) and Treg (adjusted p=0.018) after multivariable and multiple testing adjustment. In patients receiving anti-CTLA4, Th17 populations demonstrated an acquired non-classical Th1-like phenotype characterized by upregulation of the Th1-related transcription factor T-BET (p=0.04). Assessment of the peripheral cytokine signatures showed an increase in Th1-associated cytokines in combination ICI recipients, particularly the IFNg inducible cytokines MIG (adjusted p=0.021), IP-10 (adjusted p=0.021).
Conclusions
Our results confirm prior reports that anti-CTLA4 therapy is associated with augmentation of Th17 cell subsets but show that anti-CTLA4 may also contribute to a Th1-like program as a result of lineage plasticity.
Legal entity responsible for the study
Johns Hopkins, Genentech/Roche.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
M. Baretti: Financial Interests, Personal, Other, Personal Fees: AstraZeneca, Incyte. G.S. Chandler: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche. R. Mohindra: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. E.M. Jaffee: Financial Interests, Personal, Other: Abmeta; Financial Interests, Personal, Other, Personal Fees: Genocea, Achilles, DragonFly, Candel Therapeutics, Carta, NextCure; Financial Interests, Personal and Institutional, Research Grant: Lustgarten, Genentech, Break Through Cancer; Financial Interests, Institutional, Research Grant: AstraZeneca. W.J. Ho: Financial Interests, Personal, Royalties: Rodeo/Amgen; Financial Interests, Personal and Institutional, Research Grant: Sanofi, NeoTX, Circle Pharma; Financial Interests, Personal, Speaker, Consultant, Advisor: Exelixis. M. Yarchoan: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Exelixis, Genentech, Replimune, Hepion, Lantheus; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, Exelixis, Genentech, Incyte; Financial Interests, Personal, Officer: Adventris Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract